Skip to main content
. 2014 Apr 18;5(9):2778–2791. doi: 10.18632/oncotarget.1916

Figure 4. Concurrent downregulation of IDO and BRCA2 sensitized tumor cells to olaparib to a greater degree than knockdown of either target alone.

Figure 4

(A) BRCA2 protein downregulation after siRNA transfection. Bars represent the mean of two measurements. (B) Bars indicate the mean relative proliferation of cells from a representative experiment (n=3) ± SD. Each value was derived from data obtained from cells independently transfected with BRCA2 siRNA and treated with olaparib. Bars were normalized to values obtained from clones treated with IFN gamma but untreated with olaparib or siRNA; those cells were each considered to have proliferate at a 100% level after IFN gamma treatment. **Different from treatment with either siRNA alone (p≤0.05). (C) Data from panel B rearranged to show the effect of combined IDO and BRCA2 downregulation on A549 clonal population sensitivity to olaparib. *Different from values shown for lanes 6 and 7 (p≤0.05, Student's t test).